Cargando…

Tyrosine Kinase Inhibition Regulates Early Systemic Immune Changes and Modulates the Neuroimmune Response in α-Synucleinopathy

OBJECTIVES: Neuro-inflammation is common in α-Synucleinopathies and Tauopathies; and evidence suggests a link between the tyrosine kinase Abl and neurodegeneration. Abl upregulates α-Synuclein and promotes Tau hyper-phosphorylation (p-Tau), while Abl inhibitors facilitate autophagic clearance. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hebron, Michaeline L., Lonskaya, Irina, Olopade, Paul, Selby, Sandra T., Pagan, Fernando, Moussa, Charbel E-H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4308054/ https://www.ncbi.nlm.nih.gov/pubmed/25635231 http://dx.doi.org/10.4172/2155-9899.1000259

Ejemplares similares

Tyrosine kinase inhibition increases functional parkin-Beclin-1 interaction and enhances amyloid clearance and cognitive performance
por: Lonskaya, Irina, et al.
Publicado: (2013)

Ubiquitination Increases Parkin Activity to Promote Autophagic α-Synuclein Clearance
por: Lonskaya, Irina, et al.
Publicado: (2013)

Two sides of the same coin: tyrosine kinase inhibition in cancer and neurodegeneration
por: Hebron, Michaeline, et al.
Publicado: (2015)

Tau deletion impairs intracellular β-amyloid-42 clearance and leads to more extracellular plaque deposition in gene transfer models
por: Lonskaya, Irina, et al.
Publicado: (2014)

Fractalkine Mediates Communication between Pathogenic Proteins and Microglia: Implications of Anti-Inflammatory Treatments in Different Stages of Neurodegenerative Diseases
por: Desforges, Nicole M., et al.
Publicado: (2012)

Multikinase Abl/DDR/Src Inhibition Produces Optimal Effects for Tyrosine Kinase Inhibition in Neurodegeneration
por: Fowler, Alan J., et al.
Publicado: (2019)

Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer’s disease
por: Moussa, Charbel, et al.
Publicado: (2017)

Long‐Term Safety and Clinical Effects of Nilotinib in Parkinson's Disease
por: Pagan, Fernando L., et al.
Publicado: (2020)

Novel Ubiquitin Specific Protease-13 Inhibitors Alleviate Neurodegenerative Pathology
por: Liu, Xiaoguang, et al.
Publicado: (2021)

Safety, target engagement, and biomarker effects of bosutinib in dementia with Lewy bodies
por: Pagan, Fernando L., et al.
Publicado: (2022)

4564 Nilotinib alters microRNAs that regulate specific autophagy and ubiquitination genes in the cerebrospinal fluid of Parkinson’s patients
por: Fowler, Alan, et al.
Publicado: (2020)

Pathogenic Impact of α-Synuclein Phosphorylation and Its Kinases in α-Synucleinopathies
por: Kawahata, Ichiro, et al.
Publicado: (2022)

CSF MicroRNAs Reveal Impairment of Angiogenesis and Autophagy in Parkinson Disease
por: Fowler, Alan J., et al.
Publicado: (2021)

Autonomic Dysfunction in α-Synucleinopathies
por: Mendoza-Velásquez, José Javier, et al.
Publicado: (2019)

Selective vulnerability in α-synucleinopathies
por: Alegre-Abarrategui, Javier, et al.
Publicado: (2019)

Inhibition of discoidin domain receptor (DDR)-1 with nilotinib alters CSF miRNAs and is associated with reduced inflammation and vascular fibrosis in Alzheimer’s disease
por: Stevenson, Max, et al.
Publicado: (2023)

Inhibition of Bruton Tyrosine Kinase Reduces Neuroimmune Cascade and Promotes Recovery after Spinal Cord Injury
por: Yu, Chen Guang, et al.
Publicado: (2021)

Immunotherapies in Huntington's disease and α-Synucleinopathies
por: Fatoba, Oluwaseun, et al.
Publicado: (2020)

Neurons and Glia Interplay in α-Synucleinopathies
por: Mavroeidi, Panagiota, et al.
Publicado: (2021)

Autophagy in α-Synucleinopathies—An Overstrained System
por: Fellner, Lisa, et al.
Publicado: (2021)

Inhibition of Ubiquitin-Specific Protease-13 Improves Behavioral Performance in Alpha-Synuclein Expressing Mice
por: Liu, Xiaoguang, et al.
Publicado: (2022)

Dysregulated Lipid Metabolism and Its Role in α-Synucleinopathy in Parkinson’s Disease
por: Alecu, Irina, et al.
Publicado: (2019)

The Interplay between α-Synuclein and Microglia in α-Synucleinopathies
por: Deyell, Jacob S., et al.
Publicado: (2023)

Pantothenate kinase-associated neurodegeneration is not a synucleinopathy
por: Li, A, et al.
Publicado: (2013)

LAG3 is not expressed in human and murine neurons and does not modulate α‐synucleinopathies
por: Emmenegger, Marc, et al.
Publicado: (2021)

Intestinal Microbiota as Modulators of the Immune System and Neuroimmune System: Impact on the Host Health and Homeostasis
por: Maranduba, Carlos Magno da Costa, et al.
Publicado: (2015)

Drug Targeting of α-Synuclein Oligomerization in Synucleinopathies
por: Outeiro, Tiago Fleming, et al.
Publicado: (2008)

Leukotriene Signaling as a Target in α-Synucleinopathies
por: Strempfl, Katharina, et al.
Publicado: (2022)

Alteration of Autophagy and Glial Activity in Nilotinib-Treated Huntington’s Disease Patients
por: Anderson, Karen E., et al.
Publicado: (2022)

Modulation of α-synuclein expression in transgenic animals for modelling synucleinopathies — is the juice worth the squeeze?
por: Buchman, Vladimir L., et al.
Publicado: (2008)

Gene Therapy to Modulate Alpha-Synuclein in Synucleinopathies
por: Sandoval, Ivette M., et al.
Publicado: (2021)

Gastrointestinal Biopsy Obtained During Cancer Screening, a Biological Marker for α-Synucleinopathy?
por: Jotanovic, Jelena, et al.
Publicado: (2022)

Disease modifying effect of adiponectin in model of α-synucleinopathies
por: Sekiyama, Kazunari, et al.
Publicado: (2014)

Histone Deacetylase 6 and the Disease Mechanisms of α-Synucleinopathies
por: Lemos, Miguel, et al.
Publicado: (2020)

Immunotherapy Targeting Neurodegenerative Proteinopathies: α-Synucleinopathies and Tauopathies
por: Shin, Junghwan, et al.
Publicado: (2020)

STING mediates neurodegeneration and neuroinflammation in nigrostriatal α-synucleinopathy
por: Hinkle, Jared T., et al.
Publicado: (2022)

Propagative α-synuclein seeds as serum biomarkers for synucleinopathies
por: Okuzumi, Ayami, et al.
Publicado: (2023)

α-Synuclein oligomers and fibrils: partners in crime in synucleinopathies
por: Bigi, Alessandra, et al.
Publicado: (2023)

α-Synuclein interacts directly but reversibly with psychosine: implications for α-synucleinopathies
por: Abdelkarim, Hazem, et al.
Publicado: (2018)

α-Synuclein conformers reveal link to clinical heterogeneity of α-synucleinopathies
por: Schmitz, Matthias, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bth15o6bo1hcgvup731i8aspk3